SCHEMBL5599765

SCHEMBL5599765

NC(=O)c1cc(C(=O)O)n[nH]1

nearest known ligand 0.53

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 15/20 0.53
DAO P14920 1/20 0.53
HCAR3 P49019 3/20 0.48
CYTH3 O43739 1/20 0.48
BTK Q06187 1/20 0.48
EPN1 Q9Y6I3 1/20 0.48
MAPK1 P28482 1/20 0.44
PLA2G10 O15496 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827221 0.87 MAPK1 (0.47) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL70577 0.85 HCAR2 (0.59) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL8068037 0.83 ALPL (0.47) HCAR2DAOHCAR3CYTH3BTK
Water SCHEMBL1267709 0.83 HCAR2 (0.57) HCAR2DAOHCAR3CYTH3BTK
Hydrochloric Acid SCHEMBL11595364 0.83 HCAR2 (0.57) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL19987833 0.83 HCAR2 (0.57) HCAR2DAOHCAR3CYTH3BTK
Hydrochloric Acid SCHEMBL7723258 0.83 HCAR2 (0.57) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL28638090 0.83 HCAR2 (0.57) HCAR2DAOHCAR3CYTH3BTK
Ammonia Solution, Strong SCHEMBL28463590 0.81 HCAR2 (0.55) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL12168148 0.79 HCAR2 (0.59) HCAR2DAOHCAR3CYTH3BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ARENA PHARMACEUTICALS, INC. (US) 2007-02-08 US claimed
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ARENA PHARMACEUTICALS, INC. (US) 2007-02-08 US disclosed
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ARENA PHARMACEUTICALS, INC. (US) 2007-02-08 US disclosed
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ARENA PHARMACEUTICALS, INC. (US) 2007-02-08 US disclosed
EP-1633351-A1 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES Arena Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
WO-2005011677-A1 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES ARENA PHARMACEUTICALS, INC. (US) 2005-02-10 WO disclosed
EP-0244075-A1 Gametocidal pyrazoles ELI LILLY AND COMPANY (US) 1987-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ACE, AGTR2, ACE2 HCAR2 52/4885DAO 2261/4885HCAR3 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.